Dr. John F. Brandsema, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
PA license MD448845 -
Neurology Physician
PA license MD448845
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
- Childrens Health Care Associates Inc (220 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Needle measurement of electrical activity in arm or leg muscles, complete study | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 12 companies reported 77 payments worth $81,614 in total to this clinician.
| Sarepta Therapeutics, Inc. | $44,860 |
|---|---|
| Novartis Pharmaceuticals Corporation | $7,641 |
| Janssen Scientific Affairs, LLC | $6,587 |
| Itf Therapeutics LLC | $6,525 |
| Genentech USA, Inc. | $5,099 |
| Biogen, Inc. | $4,603 |
| Argenx US, Inc. | $2,138 |
| Mesoblast, Inc. | $2,000 |
| Consulting Fee | $63,003 |
|---|---|
| Travel and Lodging | $12,142 |
| Honoraria | $3,540 |
| Food and Beverage | $2,930 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Oct 20, 2025 | Consulting Fee | $13,840 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee Elevidys · Genetic Disease | $11,815 |
| Sarepta Therapeutics, Inc. Oct 6, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $8,398 |
| Janssen Scientific Affairs, LLC Dec 20, 2025 | Consulting Fee | $5,150 |
| Sarepta Therapeutics, Inc. Sep 9, 2025 | Consulting Fee | $4,725 |
| Biogen, Inc. Dec 1, 2025 | Consulting Fee SPINRAZA · Neurology | $4,100 |
| Itf Therapeutics LLC Jan 17, 2025 | Consulting Fee | $3,510 |
| Novartis Pharmaceuticals Corporation Mar 15, 2025 | Consulting Fee ZOLGENSMA · Neurology | $3,375 |
| Sarepta Therapeutics, Inc. Apr 24, 2025 | Consulting Fee Elevidys · Genetic Disease | $3,375 |
| Genentech USA, Inc. Jun 24, 2025 | Consulting Fee Evrysdi · Neurology | $2,900 |
All 39 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee | $1,688 |
| Mesoblast, Inc. Dec 22, 2025 | Consulting Fee Ryoncil · Steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patie | $2,000 |
| Janssen Scientific Affairs, LLC Dec 20, 2025 | Consulting Fee | $5,150 |
| Genentech USA, Inc. Dec 17, 2025 | Consulting Fee Evrysdi · Neurology | $1,088 |
| Janssen Scientific Affairs, LLC Dec 17, 2025 | Travel and Lodging travel to CHICAGO, IL | $199 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $671 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $198 |
| Janssen Scientific Affairs, LLC Dec 12, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $181 |
| Biogen, Inc. Dec 1, 2025 | Consulting Fee SPINRAZA · Neurology | $4,100 |
| Catalyst Pharmaceuticals, Inc. Nov 11, 2025 | Honoraria AGAMREE · NEUROLOGY | $1,200 |
| Sarepta Therapeutics, Inc. Oct 30, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $67.94 |
| Sarepta Therapeutics, Inc. Oct 30, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $67.70 |
| Sarepta Therapeutics, Inc. Oct 30, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $45.95 |
| Sarepta Therapeutics, Inc. Oct 30, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $45.54 |
| Sarepta Therapeutics, Inc. Oct 20, 2025 | Consulting Fee | $13,840 |
| Sarepta Therapeutics, Inc. Oct 6, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $8,398 |
| Sarepta Therapeutics, Inc. Oct 6, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $281 |
| Sarepta Therapeutics, Inc. Oct 6, 2025 | Travel and Lodging Exondys 51 · Genetic Disease · travel to Vienna, Austria · in-kind | $108 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Consulting Fee | $2,025 |
| Sarepta Therapeutics, Inc. Sep 9, 2025 | Consulting Fee | $4,725 |
| Sarepta Therapeutics, Inc. Aug 26, 2025 | Consulting Fee | $675 |
| Itf Therapeutics LLC Jul 24, 2025 | Honoraria | $2,340 |
| Argenx US, Inc. Jul 18, 2025 | Consulting Fee | $2,138 |
| Genentech USA, Inc. Jun 24, 2025 | Consulting Fee Evrysdi · Neurology | $2,900 |
| Genentech USA, Inc. Jun 24, 2025 | Travel and Lodging Evrysdi · Neurology · travel to Anaheim, CA | $300 |
| Genentech USA, Inc. Jun 24, 2025 | Travel and Lodging Evrysdi · Neurology · travel to Anaheim, CA | $184 |
| Csl Behring Apr 26, 2025 | Consulting Fee Privigen · Immunology | $600 |
| Sarepta Therapeutics, Inc. Apr 24, 2025 | Consulting Fee Elevidys · Genetic Disease | $3,375 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee Elevidys · Genetic Disease | $11,815 |
| Sarepta Therapeutics, Inc. Mar 16, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $79.66 |
| Novartis Pharmaceuticals Corporation Mar 15, 2025 | Consulting Fee ZOLGENSMA · Neurology | $3,375 |
| Sarepta Therapeutics, Inc. Mar 15, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Dallas, TX · in-kind | $463 |
| Sarepta Therapeutics, Inc. Mar 15, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Dallas, TX · in-kind | $283 |
| Sarepta Therapeutics, Inc. Mar 15, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Dallas, TX · in-kind | $23.43 |
| Itf Therapeutics LLC Jan 18, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $28.95 |
| Itf Therapeutics LLC Jan 17, 2025 | Consulting Fee | $3,510 |
| Itf Therapeutics LLC Jan 14, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $449 |
| Itf Therapeutics LLC Jan 14, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $37.92 |
| Itf Therapeutics LLC Jan 14, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $30.94 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $1,188,133 in research payments for these studies, mostly to the institutions running them.
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Sarepta Therapeutics, Inc. · Active, not recruiting · NCT05881408 - An open-label extension study to evaluate the long-term safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of zilucoplan in pediatric study participants with acetylcholine receptor antibody positiv…
UCB SA - A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB SA · Recruiting · NCT06055959 - Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Itf Therapeutics LLC · Recruiting · NCT03373968 - A Phase 3, Open label, Single arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab Administered Intravenously in Pediatric Participants (6 to 18 years of age) …
Alexion Pharmaceuticals, Inc. - A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec
Biogen, Inc. - A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC - Two Dose Levels of Privigen in Pediatric CIDP
Csl Behring · Recruiting · NCT03684018
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.